Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxie rats

Journal of Clinical Investigation

Volumn 97, Issue 1, 1996, Pages 172-179

  Cohen, Alan H ^a   Hanson, Kimberly ^b   Morris, Ken ^a   Fouty, Brian ^a   McMurtry, Ivan F ^a   Clarke, William ^b   Rodman, David M ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Cyclic GMP; E4021; Endothelial derived relaxing factor; Nitric oxide; Zaprinast

Indexed keywords

1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; CYCLIC GMP; CYCLIC GMP PHOSPHODIESTERASE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HYPOXIC LUNG VASOCONSTRICTION; ISOLATED LUNG; LUNG ARTERY PRESSURE; LUNG RESISTANCE; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; VASODILATATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; ANOXIA; CALCIUM CHANNEL BLOCKERS; CYCLIC GMP; DILTIAZEM; HEMODYNAMIC PROCESSES; HYPERTENSION, PULMONARY; LUNG; MALE; NITRIC OXIDE; PERFUSION; PHOSPHODIESTERASE INHIBITORS; PIPERIDINES; PULMONARY CIRCULATION; PURINONES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 0030070656     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118386     Document Type: Article

References (37)

1. Fratacci, M., C. G. Frostell, T. Chen, J C. Wain, D. R. Robinson, and W. M. Zapol. 1991. Inhaled nitric oxide a selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep Anesthesiology 75:990-999.
2. Rich, G. F., C. M. Roos, S. M Anderson, D. C. Urich, M. O. Daugherty, and R. A. Johns. 1993 Inhaled nitric oxide: dose response and the effects of blood in the isolated rat lung J Appl Physiol. 75:1278-1284.
3. Adnot, S., C. Kouyoumdjian, C. Defouilloy, P. Andnvet, S. Sediame, R Herigault, and M. Fratacci. 1993. Hcmodynamic and gas exchange responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension. Am. Rev. Respir. Dis. 148:310-316.
4. Bigatello, L. M , W. E. Hurford, R M. Kacmarek, J D. Roberts, and W. M. Zapol. 1994. Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome. Effects on pulmonary hemodynamics and oxygenation. Anesthesiology 80:761-770.
5. Kinsella, J. P., and S. H Abman 1994. Efficacy of inhalation nitric oxide therapy in the clinical management of persistent pulmonary hypertension of the newborn. Chest 115(Suppl.):92-94.
6. Kinsella, J. P., S. R. Neish, D. D. Ivy, E. Shaffer, and S. H. Abman. 1993. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. J. Pediatr. 123:103-108
7. Barst, R. J., L. J. Rubin, M.D. McGoon, E.J Caldwell, W.A. Long, and P.S. Levy. 1994. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. 121:409-415
8. Braner, D. A. V , J R. Fineman, R. Chang, and S. J. Soiffer. 1993 M&B22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol. 264:H252-H258
9. Tiktinsky, M. H., J J. Cummings. and F. C. Morin. III 1992. Acetylcholine increases pulmonary blood flow in intact fetuses via endothelium-dependent vasodilation. Am J. Physiol 262(Heart Circ. Physiol 57):H406-H410.
10. Oka, M K., K. Hasunuma, S. A. Webb, T. J. Stelzner, D. M. Rodman and I. F. McMurtry. 1993. EDRF suppresses an unidentified vasoconstrictor mechanism in hypertensive rat lungs. Am. J Physiol. 264(Lung Cell. Mol. Physiol. 8):L587-597.
11. Russ, R. D., and B. R. Walker 1993 Maintained endothelium-dependenl pulmonary vasodilation following chronic hypoxia in the rat. J. Appl Physiol. 74:339-344.
12. Isaacson, T. C., V. Hampl, E K Weir, D. P. Nelson, and S. L Archer. 1994. Increased endothelium derived NO in hypertensive pulmonary circulation of chronically hypoxic rats. J Appl Physiol 76.933-940.
13. Shaul, P. W , A. M. North, T. S Brannon, K. Ujiie, L. B. Wells, P. A. Nisen. C. J. Lowenstein, S. II. Snyder. and R. A. Star. 1995. Prolonged in vivo hypoxia enhances mtric oxide synthase type 1 and type III gene expression in adult rat lung. Am. J. Respir. Cell Mol Biol 13:167-174
14. Fineman, J. R., R. Chang, and S. J. Soifer. 1992. EDRF inhibition augments pulmonary hypertension in intact newborn lambs. Am. J Physiol 262(Heart Circ. Phyaol. 31):H1365-H1371.
15. Baudouin, S. V., P Bath, J. F. Martin, R. DuBois, and T. W. Evans. 1993. L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. Br. J. Clin. Pharmucol. 36:45-49.
16. Surdacki, A., K. Zmudka, K. Bieron, E. Kostka-Trabka, J. S Dubiel, and R. J. Gryglewski. 1994. Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension. Wien. Klin. Wochenschr. 106:421-526.
17. Popescu, L. M., C. Panoin, M. Hinescue, and D. Nutu. 1985. The mechanism of cGMP-induced relaxation in vascular smooth muscle. Eur. J. Pharmacol 107:393-394.
18. Schoeffler, P., C. Lugnier, F. Demesy-Waeldele, and J. C. Stodet. 1987. Role of cyclic AMP and cyclic GMP phosphodicstcrascs in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta Biochem. Pharmacol. 36.3965-3972
19. Souncss, J. E., R. Brazdil, B. K. Diocee, and R. Jordan. 1989. Role of selective cyclic GMP phosphodiesterae inhibition in the myorelaxant acts of M&B 22, 948, MY - 5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br J Pharmacol. 98:725-734.
20. Ahn, H. S., W. Crim, B Pitts, and E. J. Sybertz, 1992. Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases: tissue distribution, drug sensitivity and regulation of cyclic GMP levels. In Advances in Second Messenger and Phosphoprotein Research. Vol. 25. S. J. Stradz and H. Hidaka, editors. Raven Press Ltd., New York. 271-288.
21. Zeigler, J. W., D. D. Ivy, J. J. Fox, J. P Kinsella, W. R Clarke, and S. H. Abman. 1995. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus Am. J. Physiol. In press.
22. Beavo, J. A., J. G. Hardman, and E. W. Sutherland. 1970. Hydrolysis of cyclic guanosine and adenosine 3′, 5′-monophosphates by rat and bovine tissues J Biol. Chem. 245:5649-5655
23. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protem-dye binding. Anal. Biochem. 72:248-254
24. Hideyuki, A., T. Saeki, N. Mori, and I. Saito. 1994. Cardiohemodynamic characteristics of a novel, selective and potent phosphodiesterase V inhibitor, E4021. in the pig JPN. J. Pharmacol. 64:329a. (Abstr.)
25. McMurtry, I F., M. Oka, K Hasunuma, J. Yamaguchi, K Morris, and D. Rodman, Role of EDRF in control of normoxic and hypoxic pulmonary vascular tone. 1992. In High Altitude Medicine. U. Veda, J. T. Reeves, and M. Sekiguchi, editors, Shinshu University Press, Matsumoto-shi, Japan. 131-138.
26. Stamler, J. S., E. Loh. M. A. Roddy, K. E. Currie, and M. A. Creager 1994. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 89:2035-2040.
27. McMahon, T. J., L. J. Ignarro, and P. J. Kadowitz. 1993. Influence of zapnnast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J. Appl. Physiol 74:1704-1711.
28. Dundore, R. L., P. G. Habeeb, P. F. Pratt, L. T. Becker, D. M Clas. and R. A. Buchholz. 1992. Differential hemodynamic responses to selective inhibitors of cyclic nucleotide phosphodiesterases in conscious rats. J Cardiovasc Pharmacol. 19:937-944.
29. Clarke, W. R., S. Vezono, A. Chambers, and P. Doepfner. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm. Pharmacol 7:81-89.
30. Rosenkrantz, J. G., F P. Lynch, and J. H. K. Vogel. 1972. Hypoxie pulmonary hypertension: its modification by dipyridamole. J. Surg. Res 12:330-333
31. Mlczoch, J., E. K. Weir, and R. F. Grover. 1977. Inhibition of hypoxic pulmonary vasoconstriction by dipyridamole is not platelet mediated. Can J. Physiol. Pharm. 55:448-151.
32. Adachi, H., S. Yoshitake, and I. Saito. 1995 Cardiohemodynamic profile of E4021, a selective and potent phosphodiesterase type V inhibitor, in anesthestized pigs. 1994. JPN. J. Pharmacol. 64:329P.
33. Oka, M , K. G. Morris, and I. F. McMurtry 1993. NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension. J. Appl. Physiol. 75:1075-1080.
34. Ziegler, J. W., D. D. Ivy, J. J. Fox, J. P. Kinsella, W. R Clarke, and S. H. Abman. 1995. Hemodynamic effects of cGMP phosphodiesterase inhibitors during chronic pulmonary hypertension in the ovine fetus. Pediatr. Res. 37: 38a. (Abstr.)
35. Rich, S., E. Kaufmann, and P. S. Levy. 1992. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl J Med. 32776-81.
36. Giaid, A., and D. Saleh. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333:214-221.
37. Morice, A. H., J. Pepke-Zaba, M. J. Brown, P. S. Thomas, and T N. Higenbottom. 1990. Atrial natriuretic peptide in primary pulmonary hypertension. Eur. Respir. J. 3-910-913